{"analyses":[{"ciLowerLimit":".93","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.26","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":".31","paramType":"Hazard Ratio (HR)","paramValue":"1.08","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"86","upperLimit":"88.8","value":"87.5"},{"groupId":"OG001","lowerLimit":"84.2","upperLimit":"87.2","value":"85.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2426"},{"groupId":"OG001","value":"2425"}],"units":"Participants"}],"description":"Duration of time from randomization to the first indication of the following events: invasive recurrence at local (including recurrence restricted to the breast after breast conserving treatment), regional or distant sites; a new invasive cancer in the contralateral breast; any second (non-breast) invasive malignancy; or a death without prior cancer event. Appearance of DCIS or LCIS either in the ipsilateral or in the contralateral breast was not be considered as an event for DFS. In the absence of an event, DFS was censored at the date of last follow-up visit.","dispersionType":"95% Confidence Interval","groups":[{"description":"Continuous letrozole: 5 years continuously (2.5 mg Letrozole daily)\n\nLetrozole: Film-coated tablet, oral use, 2.5 mg Letrozole daily for 5 years continuously","id":"OG000","title":"Arm A: Continuous Letrozole"},{"description":"Intermittent letrozole: 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -\\> 36 mo) plus 1 x 12 mo in yr 5 -\\> 48 months\n\nLetrozole: Film-coated tablet, oral use, 2.5 mg daily, 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -\\> 36 mo) plus 1 x 12 mo in yr 5 -\\> 48 months","id":"OG001","title":"Arm B: Intermittent Letrozole"}],"paramType":"NUMBER","populationDescription":"Intention-to-treat","reportingStatus":"POSTED","timeFrame":"5-year estimates, reported at a median follow-up of 60 months","title":"Disease-free Survival (DFS)","type":"PRIMARY","unitOfMeasure":"percentage of patients"}